Mar 16, 2022 / 02:15PM GMT
Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
All right. Hello, and welcome. My name is Michael Schmidt. I'm a senior biotech analyst with Guggenheim Securities. I'm joined today by my colleague, Seamus Fernandez, our pharma analyst. And we're super excited to be hosting Bristol-Myers Squibb today at our Targeted Protein Degradation Conference.
With us today, we have Rupert Vessey. Rupert, I'm just going to -- welcome. Thanks for joining us. And I'm just going to let you introduce yourself, maybe just briefly mention your background and your current role at Bristol.
Rupert Vessey - Bristol-Myers Squibb Company - Executive VP and President of Research & Early Development
Thanks, Michael. It's great to be here. I'm Rupert Vessey. I'm President of Research and Early Development at Bristol-Myers Squibb. I'm a physician scientist by background, and I've been working in the industry for about 25 years in a whole range of different aspects of discovery, early development and translational medicine.
Bristol-Myers Squibb Co at Guggenheim Healthcare Talks: Targeted Protein Degradation Day (Virtual) - Fireside Chat Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot